Myeloma Crowd has launched an online tool called HealthTree, aimed at helping patients with multiple myeloma find the most…
Articles by Patricia Inácio, PhD
Amgen is seeking to expand the approval of its proteasome inhibitor Kyprolis (carfilzomib) in the U.S. to include once-weekly dosing…
The U.S. Food and Drug Administration granted priority review to Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Empliciti (elotuzumab)…
The U.S. Food and Drug Administration has granted orphan drug status to SRF231 to treat multiple myeloma, according to …
Expanded use of Darzalex (daratumumab) in combination with standard therapy for treating adult patients with newly-diagnosed multiple myeloma, and who are…
Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients…
Adding Empliciti (elotuzumab) to a combination of Pomalyst (pomalidomide) and dexamethasone significantly delays disease worsening or death in myeloma patients who failed…
While the best described cancer mutations are in regions that provide instructions to make proteins, most mutations actually happen in…
Updated clinical trial data show that selinexor added to standard therapies can benefit multiple myeloma patients who have failed multiple…
The investigational cancer vaccine galinpepimut-S (GPS) has been designated an orphan drug by the U.S. Food and Drug Administration…